Abstract
Purpose
The serum calcium/phosphorus (Ca/P) ratio is an accurate tool to differentiate patients with primary hyperparathyroidism (PHPT) from healthy subjects. However, other disorders of the Ca–P metabolism might impair the Ca/P ratio, such as hypophosphatemia (HypoP) not PHPT related. The aim of this study is to examine the diagnostic value of Ca/P ratio in the diagnosis of PHPT and HypoP not PHPT related.
Methods
Single-center, retrospective, case–control study, including 150 patients with PHPT and 306 patients with HypoP, compared with 150 controls. HypoP patients were enrolled among HIV-infected patients by selecting those with Fanconi-like syndrome due to antiretroviral treatment. Parameters which were measured were serum Ca, P, parathyroid hormone (PTH), 25-OH vitamin D, albumin and creatinine).
Results
The Ca/P ratio was significantly higher in PHPT and HypoP patients, compared to controls (p < 0.0001). At receiver operator characteristic (ROC) curve analysis, the cut-off of 3.56 (2.75 SI) for Ca/P ratio was able to identify patients with PHPT and HypoP (sensitivity 95%; specificity 93%). Among patients with Ca/P ratio above 3.56, the thresholds of 10.3 mg/dL (2.6 mmol/L) for serum Ca (sensitivity 93%; specificity 98%) and 80.5 pg/mL for PTH (sensitivity 91%; specificity 91%) were defined for the specific diagnosis of PHPT.
Conclusions
The Ca/P ratio above 3.56 (2.75 SI) is a highly accurate tool to identify PHPT and HypoP not PHPT-related patients. Thanks to its simplicity, this index can be proposed as a screening and first-line examination in the diagnostic work-up when a disorder of Ca–P metabolism is suspected or should be ruled out.
Similar content being viewed by others
References
Shaker JL, Deftos L (2000) Calcium and phosphate homeostasis. In: De Groot LJ, Chrousos G, Dungan K et al (eds) Endotext. MDText.com Inc, South Dartmouth (MA)
Peacock M (2010) Calcium metabolism in health and disease. Clin J Am Soc Nephrol 5(Suppl 1):S23–S30
Madeo B, Kara E, Cioni K, Vezzani S, Trenti T, Santi D, Simoni M, Rochira V (2018) Serum calcium to phosphorous (Ca/P) ratio is a simple, inexpensive, and accurate tool in the diagnosis of primary hyperparathyroidism. JBMR Plus 2:109–117
Bilezikian JP, Brandi ML, Eastell R, Silverberg SJ, Udelsman R, Marcocci C, Potts JT Jr (2014) Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the Fourth International Workshop. J Clin Endocrinol Metab 99:3561–3569
Marcocci C, Cetani F (2011) Clinical practice. Primary hyperparathyroidism. N Engl J Med 365:2389–2397
Fraser WD (2009) Hyperparathyroidism. Lancet 374:145–158
Griebeler ML, Kearns AE, Ryu E, Hathcock MA, Melton LJ 3rd, Wermers RA (2015) Secular trends in the incidence of primary hyperparathyroidism over five decades (1965–2010). Bone 73:1–7
Christov M, Juppner H (2018) Phosphate homeostasis disorders. Best Pract Res Clin Endocrinol Metab 32:685–706
Boland JM, Tebben PJ, Folpe AL (2018) Phosphaturic mesenchymal tumors: what an endocrinologist should know. J Endocrinol Investig 41:1173–1184
Gaasbeek A, Meinders AE (2005) Hypophosphatemia: an update on its etiology and treatment. Am J Med 118:1094–1101
Marcucci G, Masi L, Ferrari S, Haffner D, Javaid MK, Kamenicky P, Reginster JY, Rizzoli R, Brandi ML (2018) Phosphate wasting disorders in adults. Osteoporos Int 29:2369–2387
Casado JL, Santiuste C, Vazquez M, Banon S, Rosillo M, Gomez A, Perez-Elias MJ, Caballero C, Rey JM, Moreno S (2016) Bone mineral density decline according to renal tubular dysfunction and phosphaturia in tenofovir-exposed HIV-infected patients. Aids 30:1423–1431
Bagnis CI, Karie S, Deray G, Essig M (2009) Hypophosphataemia: an easy strategy for diagnosis and treatment in HIV patients. Antivir Ther 14:481–488
Labarga P, Barreiro P, Martin-Carbonero L et al (2009) Kidney tubular abnormalities in the absence of impaired glomerular function in HIV patients treated with tenofovir. Aids 23:689–696
Rochira V, Zirilli L, Orlando G, Santi D, Brigante G, Diazzi C, Carli F, Carani C, Guaraldi G (2011) Premature decline of serum total testosterone in HIV-infected men in the HAART-era. PLoS One 6:e28512
Smith JD, Wilson S, Schneider HG (2018) Misclassification of calcium status based on albumin-adjusted calcium: studies in a tertiary hospital setting. Clin Chem 64:1713–1722
Boyd JC, Ladenson JH (1984) Value of laboratory tests in the differential diagnosis of hypercalcemia. Am J Med 77:863–872
Avioli LV (1968) The diagnosis of primary hyperparathyroidism. Med Clin N Am 52:451–462
Strott CA, Nugent CA (1968) Laboratory tests in the diagnosis of hyperparathyroidism in hypercalcemic patients. Ann Intern Med 68:188–202
Reiss E (1970) Primary hyperparathyroidism: a simplified approach to diagnosis. Med Clin N Am 54:131–139
Turk C, Petrik A, Sarica K, Seitz C, Skolarikos A, Straub M, Knoll T (2016) EAU guidelines on diagnosis and conservative management of urolithiasis. Eur Urol 69:468–474
Pearle MS, Goldfarb DS, Assimos DG et al (2014) Medical management of kidney stones: AUA guideline. J Urol 192:316–324
Morgan MS, Pearle MS (2016) Medical management of renal stones. BMJ 352:i52
Gambaro G, Croppi E, Coe F et al (2016) Metabolic diagnosis and medical prevention of calcium nephrolithiasis and its systemic manifestations: a consensus statement. J Nephrol 29:715–734
Camacho PM, Petak SM, Binkley N et al (2016) American Association of Clinical Endocrinologists and American College of Endocrinology Clinical Practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis—2016. Endocr Pract 22:1–42
Rossini M, Adami S, Bertoldo F et al (2016) Guidelines for the diagnosis, prevention and management of osteoporosis. Reumatismo 68:1–39
Nuti R, Brandi ML, Checchia G et al (2018) Guidelines for the management of osteoporosis and fragility fractures. Intern Emerg Med 14:85–102
Rochira V, Antonio L, Vanderschueren D (2018) EAA clinical guideline on management of bone health in the andrological outpatient clinic. Andrology 6:272–285
Vescini F, Attanasio R, Balestrieri A et al (2016) Italian association of clinical endocrinologists (AME) position statement: drug therapy of osteoporosis. J Endocrinol Invest 39:807–834
Compston J, Bowring C, Cooper A et al (2013) Diagnosis and management of osteoporosis in postmenopausal women and older men in the UK: National Osteoporosis Guideline Group (NOGG) update 2013. Maturitas 75:392–396
Chen G, Xue Y, Zhang Q et al (2015) Is normocalcemic primary hyperparathyroidism harmful or harmless? J Clin Endocrinol Metab 100:2420–2424
Silverberg SJ, Shane E, Jacobs TP, Siris E, Bilezikian JP (1999) A 10-year prospective study of primary hyperparathyroidism with or without parathyroid surgery. N Engl J Med 341:1249–1255
Lundstam K, Heck A, Mollerup C et al (2015) Effects of parathyroidectomy versus observation on the development of vertebral fractures in mild primary hyperparathyroidism. J Clin Endocrinol Metab 100:1359–1367
Eastell R, Brandi ML, Costa AG, D’Amour P, Shoback DM, Thakker RV (2014) Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the Fourth International Workshop. J Clin Endocrinol Metab 99:3570–3579
Funding
This research did not receive any specific grant from any funding agency in the public, commercial or not-for-profit sector.
Author information
Authors and Affiliations
Contributions
B. Madeo is the Principal Investigator and conceived the study, analysed the data, provided data interpretation and wrote the manuscript. S. De Vincentis collected and analyzed the data, and wrote the manuscript. E. Kara collected clinical and biochemical data. F. Vescini contributed to conceive the study. T. Trenti provided data about laboratory assays. G. Guaraldi provided clinical and biochemical data about HypoP patients. V. Rochira conceived the study, analysed the data, provided data interpretation and wrote the manuscript. All authors approved the final version of the manuscript and fully contributed to its final version.
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Ethical approval
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent
Informed consent was obtained for all individual participant included in the study.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Madeo, B., De Vincentis, S., Kara, E. et al. Reliability of calcium–phosphorus (Ca/P) ratio as a new, accurate and inexpensive tool in the diagnosis of some Ca–P disorders. J Endocrinol Invest 42, 1041–1049 (2019). https://doi.org/10.1007/s40618-019-01025-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40618-019-01025-6